Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Joaquín Gavilà"'
Autor:
Natàlia Lorman-Carbó, Olga Martínez-Sáez, Aranzazu Fernandez-Martinez, Patricia Galván, Nuria Chic, Isabel Garcia-Fructuoso, Adela Rodríguez, Raquel Gómez-Bravo, Francesco Schettini, Paula Blasco, Oleguer Castillo, Blanca González-Farré, Barbara Adamo, Maria Vidal, Montserrat Muñoz, Charles M. Perou, Marcos Malumbres, Joaquín Gavilá, Tomás Pascual, Aleix Prat, Fara Brasó-Maristany
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This study examines the biological effects of palbociclib and ribociclib in hormone receptor-positive breast cancer, pivotal to the HARMONIA prospective phase III clinical trial. We explore the downstream impacts of these CDK4/6 inhibitors,
Externí odkaz:
https://doaj.org/article/ea86ec3e16194f1f8bdd3ad02a335dd9
Autor:
Tomás Pascual, Aranzazu Fernandez-Martinez, Yash Agrawal, Adam D. Pfefferle, Nuria Chic, Fara Brasó-Maristany, Blanca Gonzàlez-Farré, Laia Paré, Guillermo Villacampa, Cristina Saura, Cristina Hernando, Montserrat Muñoz, Patricia Galván, Xavier Gonzàlez-Farré, Mafalda Oliveira, Miguel Gil-Gil, Eva Ciruelos, Patricia Villagrasa, Joaquín Gavilá, Aleix Prat, Charles M. Perou
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-11 (2024)
Abstract In this study, we performed genomic analyses of cell cycle and tumor microenvironment changes during and after ribociclib and letrozole or chemotherapy in the CORALLEEN trial. 106 women with untreated PAM50-defined Luminal B early breast can
Externí odkaz:
https://doaj.org/article/3f189cf1ef8a4f74a950d11ff22079b9
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Kevin Kelly, Matt Coffey, Tomás Pascual, Aleix Prat, Luis Manso, Thomas Heineman, Fernando Salvador, Joaquín Gavilá, Houra Loghmani, Richard Trauger, Akil Merchant, Julian Olea, Homa Dadrastoussi, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/03ed36044d9b4a3ebd44195b6772b464
Autor:
Javier Salvador Bofill, Fernando Moreno Anton, Cesar Augusto Rodriguez Sanchez, Elena Galve Calvo, Cristina Hernando Melia, Eva Maria Ciruelos Gil, Maria Vidal, Begoña Jiménez-Rodriguez, Luis De la Cruz Merino, Noelia Martínez Jañez, Rafael Villanueva Vazquez, Ruben de Toro Salas, Antonio Anton Torres, Isabel Manuela Alvarez Lopez, Joaquin Gavila Gregori, Vanesa Quiroga Garcia, Elena Vicente Rubio, Juan De la Haba-Rodriguez, Santiago Gonzalez-Santiago, Nieves Diaz Fernandez, Agusti Barnadas Molins, Blanca Cantos Sanchez de Ibargüen, Juan Ignacio Delgado Mingorance, Meritxell Bellet Ezquerra, Sonia de Casa, Asuncion Gimeno, Miguel Martin
Publikováno v:
Breast, Vol 66, Iss , Pp 77-84 (2022)
Background: Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hor
Externí odkaz:
https://doaj.org/article/dad241cf2af94fb9adb70457754b6c11
Autor:
Rubén Olivera-Salguero, Elia Seguí, Juan Miguel Cejalvo, Mafalda Oliveira, Pablo Tolosa, Maria Vidal, Marcos Malumbres, Joaquín Gavilá, Cristina Saura, Sonia Pernas, Rafael López, Mireia Margelí, Judith Balmaña, Montserrat Muñoz, Isabel Blancas, Valentina Boni, Eva Ciruelos, Elena Galve, Antonia Perelló, Rodrigo Sánchez-Bayona, Susana de la Cruz, Miguel de la Hoya, Patricia Galván, Esther Sanfeliu, Blanca Gonzalez-Farre, Valeria Sirenko, Aura Blanch-Torras, Jordi Canes, Helena Masanas, Rosa Olmos, Margarita Forns, Aleix Prat, Ana Casas, Tomás Pascual
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMetastatic breast cancer (mBC) causes nearly all BC-related deaths. Next-generation sequencing (NGS) technologies allow for the application of personalized medicine using targeted therapies that could improve patients’ outcomes. However,
Externí odkaz:
https://doaj.org/article/824e6c3277784295a0300733bf18032a
Autor:
Miguel Gil-Gil, Emilio Alba, Joaquín Gavilá, Juan de la Haba-Rodríguez, Eva Ciruelos, Pablo Tolosa, Daniele Candini, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 58, Iss , Pp 160-169 (2021)
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC), leading
Externí odkaz:
https://doaj.org/article/b91e8dfa159f483185c1f1ac86ed4294
Autor:
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/b28722479f184275ad15e398ece44187
Autor:
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-13 (2021)
Abstract Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC
Externí odkaz:
https://doaj.org/article/2eba3978bf5741538c429b49f4a590be
Autor:
Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-13 (2020)
Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We evaluated the safety
Externí odkaz:
https://doaj.org/article/b135fa020eea478cb995d917e54e49ab